| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | Romosozumab Basic information |
| Product Name: | Romosozumab | | Synonyms: | Romosozumab;Research Grade Romosozumab(DHJ48701);AMG 785;AMG785;AMG-785;CDP 7851;CDP7851;CDP-7851 | | CAS: | 909395-70-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Romosozumab Structure]() |
| | Romosozumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Romosozumab Usage And Synthesis |
| Uses | Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis[1][2]. | | in vivo | Romosozumab (30 mg/kg; s.c. twice a week for 10 weeks) converts trabecular rods into trabecular plates in cynomolgus monkeys[1].
Romosozumab (3 and 30 mg/kg; s.c. once a week for 6 or 12 months) improves bone mass,
architecture, and bone strength, and maintains bone quality at the same time in mature cynomolgus monkeys with 4 months post-ovariectomy[2]. | Animal Model: | Male cynomolgus monkeys[1] | | Dosage: | 30 mg/kg | | Administration: | Subcutaneous injection; 30 mg/kg twice a week for 10 weeks | | Result: | Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.
|
| | References | [1] Paik J, Scott LJ. Romosozumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2020 Nov;37(11):845-855. DOI:10.1007/s40266-020-00793-8
[2] Ominsky MS, et al. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys. J Bone Miner Res. 2017 Apr;32(4):788-801. DOI:10.1002/jbmr.3036 |
| | Romosozumab Preparation Products And Raw materials |
|